🇺🇸 LLY — Eli Lilly and Company

Salud Compra
← Volver

Precio actual

1.417,99 USD

Máx. histórico

1.417,99

0 días

Split 2:1 del 16/10/1997

Caída desde máximo

En máximo

Rango 52 semanas

850,51 – 1.449,68

Variación hoy

+0,61%

Cierre anterior

1.409,38

Rango de hoy

1.401,59 – 1.445,96

Volumen hoy

3.622.682

Peor caída histórica

-68,26%

08/08/2000 → 05/03/2009

Recuperado en 2064 días

Volatilidad anualizada ⓘ

27,61%

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
46,02 (puede no estar actualizado)
Dividend yield
0,49% (puede no estar actualizado)
Precio objetivo analistas
1.442,09 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 14 horas
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,47%
Fecha de pago Importe por participación
14/08/2026 1,7300 USD
15/05/2026 1,7300 USD
13/02/2026 1,7300 USD
14/11/2025 1,5000 USD
15/08/2025 1,5000 USD
16/05/2025 1,5000 USD
14/02/2025 1,5000 USD
15/11/2024 1,3000 USD
15/08/2024 1,3000 USD
15/05/2024 1,3000 USD
14/02/2024 1,3000 USD
14/11/2023 1,1300 USD
14/08/2023 1,1300 USD
12/05/2023 1,1300 USD
14/02/2023 1,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/10/2012 48,46 48,95 48,42 48,76 +0,93% 1,09% 7.990.400
03/10/2012 48,06 48,39 47,93 48,31 +0,77% 0,96% 5.763.600
02/10/2012 47,81 48,14 47,79 47,94 +0,78% 0,73% 4.948.300
01/10/2012 47,49 48,04 47,46 47,57 +0,34% 1,22% 5.301.900
28/09/2012 47,37 47,52 47,00 47,41 -0,48% 1,10% 5.941.800
27/09/2012 47,36 47,72 47,10 47,64 +0,93% 1,31% 5.020.300
26/09/2012 47,45 47,70 46,84 47,20 -0,53% 1,81% 4.792.400
25/09/2012 47,52 47,84 47,41 47,45 +0,11% 0,90% 4.395.100
24/09/2012 47,50 47,63 47,16 47,40 -0,13% 0,99% 4.873.400
21/09/2012 47,17 47,76 47,10 47,46 +0,94% 1,40% 8.368.200
20/09/2012 46,77 47,10 46,75 47,02 +0,34% 0,75% 4.905.700
19/09/2012 46,77 47,18 46,68 46,86 -0,11% 1,07% 5.176.800
18/09/2012 46,52 47,07 46,52 46,91 +0,17% 1,18% 4.155.500
17/09/2012 46,54 46,94 46,53 46,83 +0,24% 0,88% 7.230.400
14/09/2012 47,01 47,01 46,51 46,72 -0,91% 1,06% 6.510.400
13/09/2012 46,62 47,26 46,31 47,15 +1,29% 2,04% 5.501.100
12/09/2012 46,48 46,86 46,46 46,55 +0,13% 0,86% 3.977.600
11/09/2012 46,65 46,70 46,41 46,49 -0,06% 0,62% 4.263.300
10/09/2012 46,74 46,85 46,52 46,52 -0,28% 0,71% 4.721.800
07/09/2012 46,71 46,87 46,29 46,65 -0,34% 1,24% 9.900.100
06/09/2012 45,98 46,86 45,98 46,81 +2,18% 1,91% 8.553.600
05/09/2012 45,87 46,36 45,72 45,81 +1,15% 1,40% 11.305.000
04/09/2012 44,97 45,41 44,71 45,29 +0,85% 1,56% 6.948.400
31/08/2012 45,07 45,29 44,68 44,91 +0,02% 1,35% 6.397.500
30/08/2012 45,00 45,00 44,63 44,90 -0,60% 0,82% 5.234.500
29/08/2012 44,60 45,26 44,38 45,17 +1,03% 1,97% 8.328.900
28/08/2012 44,63 45,45 44,21 44,71 +0,27% 2,78% 13.256.500
27/08/2012 43,75 44,98 43,75 44,59 +1,66% 2,81% 15.116.900
24/08/2012 44,81 45,01 43,36 43,86 +3,44% 3,68% 48.000.900
23/08/2012 42,16 42,48 42,12 42,40 +0,55% 0,85% 4.589.600